Simon Berritt

机构：Pfizer (United States), PRX Research · ORCID：0000-0001-5572-6771

发表论文 81 篇 · 总被引 5261 次 · h-index 24

代表论文

• An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 (2021 · Science · 被引 1966)
• Probing the chemical ‘reactome’ with high-throughput experimentation data (2024 · Nature Chemistry · 被引 49)
• Synthetic Approaches to the New Drugs Approved During 2020 (2022 · Journal of Medicinal Chemistry · 被引 41)
• Discovery of Nirmatrelvir (PF-07321332): A Potent, Orally Active Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Main Protease (2025 · Journal of Medicinal Chemistry · 被引 27)
• Synthetic Approaches to the New Drugs Approved During 2021 (2023 · Journal of Medicinal Chemistry · 被引 27)
• Synthetic Approaches to the New Drugs Approved During 2022 (2024 · Journal of Medicinal Chemistry · 被引 24)